News >

Loncastuximab Tesirine Shows Encouraging ORR in Relapsed/Refractory DLBCL

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 09, 2020

Jay Feingold, MD, PhD, senior vice president and chief medical officer at ADC Therapeutics

Jay Feingold, MD, PhD

Loncastuximab tesirine (ADCT-402) demonstrated an overall response rate (ORR) of 45.5% in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including those who are difficult to treat, according to topline results of a pivotal phase II trial (NCT03589469).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication